Pregnancy Outcomes After Exposures to TNF-Alpha Inhibitors in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis with the Application of GRADE Assessment
Year: 2017
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: This systematic review examined on whether there are more adverse pregnancy outcomes among inflammatory bowel disease (IBD) patients taking TNF-alpha inhibitors (TNFi) in pregnancy compared to non-exposed IBD controls and healthy population. This review searched PubMed, Embase, and WoS and other sources to look for relevant studies. Two reviewers independently extracted information on 6 adverse pregnancy outcomes (SA/SB, PTB/PMB, LBW, SGA, CA) comparing TNFi-exposed group and non-exposed controls. 32 case reports, 25 case series, and 9 cohort studies were included in this review. There was no increased risk in any of the adverse pregnancy outcomes comparing TNFi-exposed group to IBD controls. There was increased risk of preterm birth (RR [95% CIs] = 2.66 [1.36, 5.19] and low birth weight (RR [95% CIs] = 2.36 [1.27, 4.36] comparing TNFi-exposed group to healthy control, which was consistent with in IBD pregnancy. Overall, there was no increased risk in adverse pregnancy outcomes after taking TNFi in IBD pregnancy.
Source: TSpace (University of Toronto)
Author: Juejing Ling
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2784552420
